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a b s t r a c t
In the present work we investigated the neuroprotective role of neuropeptide Y (NPY) after
an excitotoxic insult in rat organotypic hippocampal slice cultures. Exposure of 2 week-old
rat hippocampal slice cultures to 12 mM kainate (KA) for 24 h induced neuronal death in
dentate gyrus (DG) granular cell layer, CA1 and CA3 pyramidal cell layers, as quantified by
cellular propidium iodide (PI) uptake. The activation of Y1 or Y2 receptors 30 min after
starting the exposure to the excitotoxic insult with kainate resulted in neuroprotection by
reducing the PI uptake in DG, CA1 and CA3 cell layers. The use of Y1 or Y2 receptors
antagonists, BIBP3226 (1 mM) or BIIE0246 (1 mM), resulted in the loss of the neuroprotection
induced by the activation of Y1 or Y2 receptors, respectively, in all hippocampal subfields.
Taken together these results suggest that activation of NPY Y1 or Y2 receptors activates
neuroprotective pathways that are able to rescue neurons from excitotoxic cell death.
# 2006 Elsevier Inc. All rights reserved.
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NPY is one of the most abundant and widely distributed
neuropeptides in the mammalian central nervous system and
has been associated with a number of physiological and
pathological conditions [47]. This peptide has been shown to
modulate anxiety, pain, memory, eating behavior, and many
other functions in the central aswell as the peripheral nervous
system [16,47]. Also, the NPY system has been suggested to be
involved in excitation associated with limbic seizures [8].
Six G-protein-coupled NPY receptor subtypes have been
identified (Y1–Y6) and mediate inhibition of cAMP synthesis
[15,24,25]. In the central nervous system, and specifically in* Corresponding author at: Institute of Biochemistry, Faculty of Medic
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doi:10.1016/j.peptides.2006.09.031the hippocampus, Y1 and Y2 receptors are highly expressed
[40]. Y1 receptors are mainly located on dentate granule cells
and hilar NPY-containing interneurons [31], whereas Y2
receptors are expressed at relatively high concentrations in
terminal regions of mossy fibers and Schaffer collaterals [18].
In rats, Y1 receptor antagonists inhibit kainate-induced
seizures and delay kindling epileptogenesis, while a Y1
receptor agonist antagonizes these effects [3,13]. The activa-
tion of Y2 receptors suppresses seizure activity in hippocam-
pal slices in vitro [6,10] and in vivo models [10,45]. Also, NPY,
acting via Y2 receptor, inhibits impulse-dependent synaptic
excitation of CA3 pyramidal cells of the rat hippocampus by
presynaptic mechanisms [28]. Accordingly, the NPY systemine, University of Coimbra, 3004-504 Coimbra, Portugal.
.
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[40,43]. The role of endogenous NPY in regulating seizure
activity [43] is supported by evidence of increased NPY levels
under epileptic conditions in both inhibitory interneurons and
in excitatory granule cells which in control conditions do not
contain the peptide [44,45].
Several in vitro studies have demonstrated that, in the
hippocampus, NPY selectively inhibits glutamatergic synaptic
transmission in mossy fiber CA3 and Schaffer collaterals CA1
pyramidal cell synapses [9,14,19,28] by depressing glutamate
release [14,37] through a mechanism involving the inhibition
of the voltage-dependent Ca2+ influx in presynaptic nerve
terminals [33,36,37]. The control in excess glutamate release,
potentially relevant for hyperexcitability brain disorders, may
contribute to the identified neuroprotection properties of NPY
against excitotoxic injuries [39,40].
In the present work, we identified a post-injury (excito-
toxic) neuroprotective role for NPY that contributes to rescue
injured neurons from cell death.2. Materials and methods
2.1. Rat organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared using
the interface culture method [41] modified by Kristensen et al.
and Noraberg et al. [21,29]. The 6–8-day-old Wistar rats were
quickly decapitated in accordance with ethically approved
standard procedures (European Community guidelines for the
use of animals in the laboratory), the brains removed under
sterile conditions, and the hippocampi isolated and sectioned
into 350 mm thick slices using a McIlwain tissue chopper.
Slices were placed in cold Gey’s balanced salt solution (GBSS;
Biological Industries, Kibbutz Beit Haemek, Israel) with 25 mM
D-glucose (Merck, Darmstadt, Germany), and all excess tissue
was gently trimmed out. Six individual slices were then
transferred to each porous (0.4 mm) membrane insert (Milli-
pore Corp., Bedford, MA, USA) and inserts placed in a six-well
culture tray (Costar, Corning, NY, USA). Each well contained
1 ml of culture medium, with 50% OPTI-MEM, 25% heat-
inactivated horse serum and 25% Hank’s BSS (HBSS) (all from
Invitrogen, Paisley, UK) and supplemented with D-glucose to a
final concentration of 25 mM. The trays were kept in an
incubator with 5% CO2 and 95% atmospheric air at 36 8C. On
the third day and thereafter the medium was changed to a
chemically defined medium composed of serum-free Neuro-
basal medium (Invitrogen, Paisley, UK) supplemented with
1 mM L-glutamine (Sigma, St Louis, MO) and B-27 supplement
(Invitrogen, Paisley, UK). The medium was changed twice a
week for the next 2 weeks before starting the experiments. No
antimitotic drugs or antibiotics were used at any stage.
2.2. Monitoring propidium iodide uptake
For detection of neuronal cell death, cellular uptake of the
fluorescent dye propidium iodide (PI, 3,8-diamino-5-(3-
(diethylmethylamino)propyl)-6-phenyl phenanthridinium
diiodide; Sigma, St. Louis, MO) was recorded and quantified
according to previously described procedures [21,29]. PI is apolar compound that only enters cells with damaged cell
membranes (dead or dying cells), but once inside the cells, it
binds to DNA, emitting a bright red fluorescence (630 nm)
when exposed to blue-green light (493 nm). PI is basically non-
toxic to neurons [17,22] and has been used as an indicator of
neuronal membrane integrity [17,32] and cell damage [32,46].
Basal level of PI uptakewas determined after adding 2 mMPI to
the medium, and digital fluorescent micrographs were taken
at least 3 h later. The same concentration was also used in all
subsequent medium changes. PI uptake was recorded by
fluorescence microscopy (Axioskop 2 plus, Carl Zeiss, Go¨ttin-
gen, Germany) using a standard rhodamine filter and digital
camera (AxioCam HRc, Carl Zeiss, Go¨ttingen, Germany) with
1000 ms exposure time. After exposing the cultures to the
drugs, digital fluorescent micrographs of the cultures were
taken at different time points during the experiments, for use
in densitometric measurements of the PI uptake in CA1, CA3
pyramidal cell layers and also dentate gyrus (DG), and were
performed by delineating the different subfields using NIH
Image 1.62 analysis software (National Institutes of Health,
Bethesda, MD). The densitometric data were expressed as the
mean value  standard error of mean (S.E.M.). Statistical
analysis was performed using one-way ANOVA followed by
Dunnett’s multiple comparison test. Differences were con-
sidered significant when p < 0.05.
2.3. Exposure to neuropeptide Y receptor agonists/
antagonists
To test the role of NPY receptors in kainate-mediated neuronal
death, cultures were first pre-incubated for 30 or 60 min with
12 mM kainate. This concentration was chosen based on a
concentration-response curve inwhich the EC50 for kainate in
CA1, CA3 and DG was close to 12 mM (data not shown). After
this period, cultures were exposed to the Y1 or Y2 receptor
agonists ([Leu31,Pro34] NPY (1 mM) or NPY13–36 (300 nM),
respectively) (Bachem Bubendorf, Switzerland) for 24 h. The
same experimental protocol was used to study the effect of
1 mM BIBP3226 (Peninsula Laboratories, Belmont, CA) or 1 mM
BIIE0246 (generous gift from Dr. Henri Doods, Boehringer
Ingelheim Pharma, Germany), Y1 and Y2 receptor antagonists,
respectively. These concentrations were chosen based on
previous studies [20,39]. Control cultures were not exposed to
any drug. Digital images of PI uptakewere obtained before any
exposure (day 0) and 24 h after exposure to the NPY receptor
agonists/antagonists (day 1). Basal death (day 0) was sub-
tracted from the values at day 1.
2.4. Evaluation of cell morphology and toluidine blue
staining
Organotypic hippocampal slice cultures were prepared and
stained as described by Noraberg et al. [29]. At the end of each
experiment the cultures were fixed in 4% phosphate buffered
paraformaldehyde (PFA) overnight. Then, cultures were
washed for 1 h in 0.15 M phosphate buffer (25 mM KH2PO4,
125 mMNa2HPO42H2O), and thenwashed in distilledwater for
1 h. After this, the slices were stained with toluidine blue
solution (77 mM Na2HPO42H2O; 67.2 mM citric acid; 3.3 mM
toluidine blue) for 5 min. The slices were washed three times
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96% ethanol (2 min each), washed with distilled water (three
times) and stained once more with toluidine blue solution.
Theywere againwashedwith distilled water (three times) and
dehydrated in 70%, 96% and 99% ethanol (5 min each). After
this, the cultures were detached from the membrane, and
each culture was placed on gelatin-coated glass slides
(cultures from one insert on one glass slide). Finally the
preparations were mounted with Entellan (Merck, Darmstadt,
Germany).3. Results
3.1. Exogenous activation of Y1 and Y2 receptors can
rescue neurons from cell death following the application of
kainate
The putative neuroprotective role of Y1 and Y2 receptors
against kainate receptor-mediated excitotoxicity in CA1 and
CA3 pyramidal cell layers and in DGwas investigated. In theseFig. 1 – The activation of NPY Y1 and NPY Y2 receptor 60 min af
neuronal death in CA1 and CA3 pyramidal cell layers and in DG
12 mM kainate in CA1 (A) and CA3 (B) pyramidal cell layers and i
([Leu31,Pro34] NPY (1 mM), NPY13–36 (300 nM), respectively) on th
induced by 12 mM kainate was set to 100%. Data are shown as m
PI uptake of organotypic hippocampal slice cultures showing th
experimental situation indicated next to each photograph (D): (
exposed to 12 mM kainate, (III) culture exposed to 1 mM [Leu31,P
(IV) culture exposed to 300 nM NPY13–36 60 min after starting texperiments, themean value of PI uptake in all subfields, after
24 h exposure to 12 mM kainate (n = 37), was set to 100%,
representing maximal PI uptake. Basal PI uptake in control
conditions was 47.41  3.94% (n = 49), 40.13  3.93% (n = 49)
and 46.52  3.45% (n = 49) in CA1, CA3 pyramidal cell layers
and DG, respectively.
The activation of Y1 or Y2 receptors for 24 h, by the selective
Y1 or Y2 receptor agonists ([Leu
31,Pro34] NPY (1 mM) or NPY13–
36 (300 nM), respectively) starting at 60 min after the excito-
toxic insult with 12 mM kainate, did not protect neurons from
cell death, resulting in PI uptake similar to that obtained with
kainate alone (Fig. 1).
However, activation (for 24 h) of Y1 receptors with the Y1
receptor agonist [Leu31,Pro34] NPY (1 mM), 30 min after
starting the excitotoxic insult with 12 mM kainate, prevented
neuronal death and reduced the PI uptake to 61.50  6.14%
(n = 36), 53.49  6.37% (n = 36) and 60.20  7.42% (n = 36) in
CA1, CA3 and DG, respectively (Fig. 2). Also, Y2 receptor
activation with the Y2 receptor agonist, NPY13–36 (300 nM),
for 24 h, starting at 30 min after the excitotoxic insult was
neuroprotective and decreased PI uptake to 51.27  5.66%ter starting the insult with kainate (KA) did not prevent the
. Densitometric measurements of PI uptake induced by
n DG (C) showing the effects of Y1 and Y2 receptor agonists
e PI uptake induced by 12 mM kainate. The PI uptake
eans W S.E.M., with n = 12–49. Fluorescent micrographs of
e typical regional pattern of neuronal death induced by the
I) control culture with low basal PI uptake, (II) culture
ro34] NPY 60 min after the exposure to 12 mM kainate and
he exposure to 12 mM kainate.
Fig. 2 – NPY Y1 and NPY Y2 receptor activation 30 min post-kainate (KA) insult prevented cell degeneration in CA1 and CA3
pyramidal cell layers and in DG. Densitometric measurements of PI uptake induced by 12 mM kainate in CA1 (A) and CA3 (B)
pyramidal cell layers and in DG (C) showing the effects of Y1 and Y2 receptor agonists ([Leu
31,Pro34] NPY (1 mM), NPY13–36
(300 nM), respectively) on the PI uptake induced by 12 mMkainate. The PI uptake induced by 12 mM kainate was set to 100%.
Data are shown as meansW S.E.M., with n = 12–49 and *P < 0.05, **P < 0.01 compared to 12 mM kainate using one-way
ANOVA followed by Dunnett’s multiple comparison test. Fluorescent micrographs of PI uptake of organotypic hippocampal
slice cultures showing the typical regional pattern of neuronal death induced by the experimental situation indicated next
to each photograph (D): (I) control culture with low basal PI uptake, (II) culture exposed to 12 mM kainate, (III) culture
exposed to 1 mM [Leu31,Pro34] NPY 30min after starting the exposure to 12 mM kainate and (IV) culture exposed to 300 nM
NPY13–36 30 min after starting the exposure to 12 mM kainate.
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CA1, CA3 and DG (Fig. 2).
Evaluation ofmorphology in toluidine blue stained cultures
exposed to 12 mM kainate for 24 h indicated strong degen-
erative changes, especially in the CA3 pyramidal cell layer,
wheremany swollen neuronswith a necrotic-likemorphology
and condensed apoptotic-like nuclei were observed (Fig. 3B).
These degenerative eventswere prevented followingY1 andY2
receptor activation 30 min after starting the kainate exposure
(Fig. 3C and D).
The selectivity of the effects observed in the presence of
NPY Y1 and Y2 receptor agonists was further evaluated by
using BIBP3226 or BIIE0246 (Y1 or Y2 receptor antagonist,
respectively). The co-exposure to BIBP3226 (1 mM) and [Leu31,-
Pro34] NPY (1 mM) 30 min after starting the exposure to 12 mM
kainate resulted in the loss of the neuroprotection caused by
the activation of Y1 receptors: 84.29  15.34% (n = 12) in CA1,
116.30  16.75% (n = 12) in CA3 and 115.5  21.19% (n = 12) in
DG (Fig. 4). Similarly, co-exposure to BIIE0246 (1 mM) andNPY13-36 (300 nM) resulted in inhibition of the neuroprotec-
tive effects induced by activation of Y2 receptors in all
hippocampal subregions analyzed: 105.30  14.85% (n = 12)
in CA1, 96.87  18.13% (n = 12) in CA3 and 102.10  25.72%
(n = 12) in DG (Fig. 4).4. Discussion
We have previously shown that pre-incubation with NPY
receptor agonists, before starting an excitotoxic insult with
kainate, resulted in neuroprotection against kainate-
induced excitotoxicity in rat organotypic hippocampal slice
cultures [39]. In the present study we attempted to
determine whether NPY receptor activation after starting
the excitotoxic insult with kainate can still protect
and rescue neurons from cell death. Here we show that,
indeed, NPY Y1 and Y2 receptor activation at 30 min but not
60 min after starting kainate exposure prevents cell death
Fig. 3 – Morphological changes of cultured organotypic hippocampal slice cultures exposed to kainate (KA) for 24 h and
neuroprotection afforded by NPY receptor agonists. (A) toluidine blue stained hippocampal slice cultures in control
condition, (B) culture exposed to 12 mM kainate, (C) culture incubated with the Y1 receptor agonist ([Leu
31,Pro34] NPY (1 mM)
30 min after starting the exposure to 12 mM kainate and (D) culture incubated with the Y2 receptor agonist NPY13–36
(300 nM) after starting the exposure to 12 mM kainate. Arrow indicates swollen necrotic-like cells; arrow head indicate
condensed apoptotic-like cell nuclei. Scale bar 40 mm.
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cells.
In accordance with published reports [12,39], kainate
exposure results in both necrotic and apoptotic-like fea-
tures. Necrosis is characterized by progressive loss of
cytoplasmic integrity, rapid influx of Na+, Ca2+, and water,
resulting in cytoplasmic swelling and nuclear pyknosis
[2,4,27]. The latter feature leads to nuclear and cell
fragmentation and the release of lysosomal and granular
contents into surrounding extracellular space, causing
subsequent inflammation [7,26,30,35]. Apoptosis can be
induced by the ligation of plasma membrane death
receptors (CD95, TNF-receptor, and TNF-related apoptosis-
inducing ligand receptor), which stimulate the ‘‘extrinsic
pathway’’, or by perturbation of intracellular environment
homeostasis, the ‘‘intrinsic pathway’’ [5,11]. The intrinsic
pathway involves mitochondrial dysfunction and the
release of mitochondrial membrane proteins including
cytochrome c, which stimulates cytosolic assembly of the
apoptosome, the caspase activation complex [5,11,23].
Mitochondria participate in apoptotic and necrotic celldeath, suggesting that death/toxic signals, through common
mechanisms, can cause both apoptosis and necrosis
depending on variables such as ATP content [5].
Since NPY receptors activate signaling pathways
involved in the regulation of intracellular Ca2+ homeostasis
[38], it is possible that NPY may exert its protective effects
partially via its action on Ca2+ influx, as Thiriet et al. [42]
suggested for NPY-mediated protection against metham-
phetamine-induced neuronal apoptosis. This idea is
consistent with the demonstration that activation of both
Y1 and Y2 receptors in hippocampal cells inhibits the
increase in intracellular calcium concentration following
KCl depolarization [36,38]. Also, by inhibiting Ca2+
influx NPY may inhibit the calcium-dependent death path-
ways involving caspase and calpain activation and mito-
chondrial dysfunction [1,34], and thus prevent cell death
[39].
Taken together, the present data further support a putative
role for NPY-dependent signaling mechanisms as potential
neuroprotective targets against excitotoxic insults, able to
rescue post-insult injured neurons.
Fig. 4 – Blockade of Y1 and Y2 receptor-mediated neuroprotection by Y1 and Y2 selective antagonists. Effect of 1 mM BIBP3226
or 1 mM BIIE0246 (Y1 and Y2 receptor antagonists, respectively) on PI uptake induced by 12 mM kainate plus [Leu
31,Pro34]
NPY (1 mM) or NPY13–36 (300 nM) (Y1 and Y2 receptor agonist, respectively) in the CA1 (A) and CA3 (B) pyramidal cell layers
and in DG (C). Data are shown as means W S.E.M., with n = 12–49 and *P < 0.05, **P < 0.01 compared to the effect of 12 mM
kainate, using one-way ANOVA followed by Dunnett’s multiple comparison test.
p e p t i d e s 2 8 ( 2 0 0 7 ) 2 8 8 – 2 9 4 293Acknowledgments
This work was supported by the Foundation for Science and
Technology, Portugal, and FEDER Projects SFRH/BD/14163/
2003, POCTI/NSE/46848/2002, and POCTI/SAU-NEU/58492/
2004).We acknowledgeDr. Henri Doods (Boehringer Ingelheim
Pharma KG) for generously providing us the BIIE0246.r e f e r e n c e s
[1] Araujo IM, Xapelli S, Gil JM, Mohapel P, Petersen A, Pinheiro
PS, et al. Proteolysis of NR2B by calpain in the hippocampus
of epileptic rats. Neuroreport 2005;16(4):393–6.
[2] Barros LF, Hermosilla T, Castro J. Necrotic volume increase
and the early physiology of necrosis. Comp Biochem
Physiol A Mol Integr Physiol 2001;130(3):401–9.
[3] Benmaamar R, Pham L, Marescaux C, Pedrazzini T,
Depaulis A. Induced down-regulation of neuropeptide Y–Y1
receptors delays initiation of kindling. Eur J Neurosci
2003;18(4):768–74.
[4] Berridge MJ, Lipp P, Bootman MD. The versatility and
universality of calcium signalling. Nat Rev Mol Cell Biol
2000;1(1):11–21.[5] Bhatia M. Apoptosis versus necrosis in acute pancreatitis.
Am J Physiol Gastrointest Liver Physiol 2004;286(2):
G189–96.
[6] Bijak M, Neuropeptide Y. suppresses epileptiform activity
in rat frontal cortex and hippocampus in vitro via different
NPY receptor subtypes. Neurosci Lett 1999;268(3):115–8.
[7] Buja LM, Eigenbrodt ML, Eigenbrodt EH. Apoptosis and
necrosis. Basic types and mechanisms of cell death. Arch
Pathol Lab Med 1993;117(12):1208–14.
[8] Colmers WF, El Bahh B. Neuropeptide Y and epilepsy.
Epilepsy Curr 2003;3(2):53–8.
[9] Colmers WF, Lukowiak K, Pittman QJ. Presynaptic action of
neuropeptide Y in area CA1 of the rat hippocampal slice. J
Physiol 1987;383:285–99.
[10] El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger
AG, Sperk G, et al. The anti-epileptic actions of
neuropeptide Y in the hippocampus are mediated by Y2
and not Y5 receptors. Eur J Neurosci 2005;22(6):1417–30.
[11] Ferri KF, Kroemer G. Organelle-specific initiation of cell
death pathways. Nat Cell Biol 2001;3(11):E255–63.
[12] Fujikawa DG, Shinmei SS, Cai B. Kainic acid-induced
seizures produce necrotic, not apoptotic, neurons with
internucleosomal DNA cleavage: implications for
programmed cell death mechanisms. Neuroscience
2000;98(1):41–53.
[13] Gariboldi M, Conti M, Cavaleri D, Samanin R, Vezzani A.
Anticonvulsant properties of BIBP3226, a non-peptide
p e p t i d e s 2 8 ( 2 0 0 7 ) 2 8 8 – 2 9 4294selective antagonist at neuropeptide Y Y1 receptors. Eur J
Neurosci 1998;10(2):757–9.
[14] Greber S, Schwarzer C, Sperk G. Neuropeptide Y inhibits
potassium-stimulated glutamate release through Y2
receptors in rat hippocampal slices in vitro. Br J Pharmacol
1994;113(3):737–40.
[15] Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA.
Cloned human neuropeptide Y receptor couples to two
different second messenger systems. Proc Natl Acad Sci
USA 1992;89(13):5794–8.
[16] Hokfelt T, Broberger C, Zhang X, Diez M, Kopp J, Xu Z, et al.
Neuropeptide Y: some viewpoints on a multifaceted
peptide in the normal and diseased nervous system. Brain
Res Brain Res Rev 1998;26(2–3):154–66.
[17] Hsu SS, Newell DW, Tucker A, Malouf AT, Winn HR.
Adenosinergic modulation of CA1 neuronal tolerance to
glucose deprivation in organotypic hippocampal cultures.
Neurosci Lett 1994;178(2):189–92.
[18] Jacques D, Dumont Y, Fournier A, Quirion R.
Characterization of neuropeptide Y receptor subtypes in
the normal human brain, including the hypothalamus.
Neuroscience 1997;79(1):129–48.
[19] Klapstein GJ, Colmers WF. 4-Aminopyridine and low Ca2+
differentiate presynaptic inhibition mediated by
neuropeptide Y, baclofen and 2-chloroadenosine in rat
hippocampal CA1 in vitro. Br J Pharmacol 1992;105(2):470–4.
[20] Klapstein GJ, Colmers WF. Neuropeptide Y suppresses
epileptiform activity in rat hippocampus in vitro. J
Neurophysiol 1997;78(3):1651–61.
[21] Kristensen BW, Noraberg J, Jakobsen B, Gramsbergen JB,
Ebert B, Zimmer J. Excitotoxic effects of non-NMDA
receptor agonists in organotypic corticostriatal slice
cultures. Brain Res 1999;841(1–2):143–59.
[22] Kristensen BW, Noraberg J, Zimmer J. Comparison of
excitotoxic profiles of ATPA, AMPA, KA and NMDA in
organotypic hippocampal slice cultures. Brain Res
2001;917(1):21–44.
[23] Kroemer G, Reed JC. Mitochondrial control of cell death. Nat
Med 2000;6(5):513–9.
[24] Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H,
Wahlested C. Cloning and functional expression of a
human neuropeptide Y/peptide YY receptor of the Y1 type.
J Biol Chem 1992;267(16):10935–8.
[25] Lundell I, Berglund MM, Starback P, Salaneck E, Gehlert DR,
Larhammar D. Cloning and characterization of a novel
neuropeptide Y receptor subtype in the zebrafish. DNA Cell
Biol 1997;16(11):1357–63.
[26] Majno G, Joris I. Apoptosis, oncosis, and necrosis. An
overview of cell death. Am J Pathol 1995;146(1):3–15.
[27] Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in
the liver: a tale of two deaths? Hepatology 2006;43(2 Suppl
1):S31–44.
[28] McQuiston AR, Colmers WF. Neuropeptide Y2 receptors
inhibit the frequency of spontaneous but not miniature
EPSCs in CA3 pyramidal cells of rat hippocampus. J
Neurophysiol 1996;76(5):3159–68.
[29] Noraberg J, Kristensen BW, Zimmer J. Markers for neuronal
degeneration in organotypic slice cultures. Brain Res Brain
Res Protoc 1999;3(3):278–90.
[30] Padanilam BJ. Cell death induced by acute renal injury: a
perspective on the contributions of apoptosis and necrosis.
Am J Physiol Renal Physiol 2003;284(4):F608–27.
[31] Paredes MF, Greenwood J, Baraban SC. Neuropeptide Y
modulates a G protein-coupled inwardly rectifyingpotassium current in the mouse hippocampus. Neurosci
Lett 2003;340(1):9–12.
[32] Pozzo Miller LD, Mahanty NK, Connor JA, Landis DM.
Spontaneous pyramidal cell death in organotypic slice
cultures from rat hippocampus is prevented by
glutamate receptor antagonists. Neuroscience
1994;63(2):471–87.
[33] Qian J, Colmers WF, Saggau P. Inhibition of synaptic
transmission by neuropeptide Y in rat hippocampal area
CA1: modulation of presynaptic Ca2+ entry. J Neurosci
1997;17(21):8169–77.
[34] Rego AC, Oliveira CR. Mitochondrial dysfunction and
reactive oxygen species in excitotoxicity and apoptosis:
implications for the pathogenesis of neurodegenerative
diseases. Neurochem Res 2003;28(10):1563–74.
[35] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin
protein HMGB1 by necrotic cells triggers inflammation.
Nature 2002;418(6894):191–5.
[36] Silva AP, Carvalho AP, Carvalho CM, Malva JO. Modulation
of intracellular calcium changes and glutamate release by
neuropeptide Y1 and Y2 receptors in the rat hippocampus:
differential effects in CA1, CA3 and dentate gyrus. J
Neurochem 2001;79(2):286–96.
[37] Silva AP, Carvalho AP, Carvalho CM, Malva JO. Functional
interaction between neuropeptide Y receptors and
modulation of calcium channels in the rat hippocampus.
Neuropharmacology 2003;44(2):282–92.
[38] Silva AP, Cavadas C, Grouzmann E. Neuropeptide Y and its
receptors as potential therapeutic drug targets. Clin Chim
Acta 2002;326(1–2):3–25.
[39] Silva AP, Pinheiro PS, Carvalho AP, Carvalho CM, Jakobsen
B, Zimmer J, et al. Activation of neuropeptide Y receptors is
neuroprotective against excitotoxicity in organotypic
hippocampal slice cultures. FASEB J 2003;17(9):1118–20.
[40] Silva AP, Xapelli S, Grouzmann E, Cavadas C. The putative
neuroprotective role of neuropeptide Y in the central
nervous system. Curr Drug Targets CNS Neurol Disord
2005;4(4):331–47.
[41] Stoppini L, Buchs PA, Muller D. A simple method for
organotypic cultures of nervous tissue. J Neurosci Methods
1991;37(2):173–82.
[42] Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W,
Goldberg SR, et al. Neuropeptide Y protects against
methamphetamine-induced neuronal apoptosis in the
mouse striatum. J Neurosci 2005;25(22):5273–9.
[43] Tu B, Timofeeva O, Jiao Y, Nadler JV. Spontaneous release
of neuropeptide Y tonically inhibits recurrent mossy fiber
synaptic transmission in epileptic brain. J Neurosci
2005;25(7):1718–29.
[44] Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D,
Ravizza T, Richichi C, et al. Seizure susceptibility and
epileptogenesis are decreased in transgenic rats
overexpressing neuropeptide Y. Neuroscience
2002;110(2):237–43.
[45] Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging
evidence for a functional role in seizure modulation.
Trends Neurosci 1999;22(1):25–30.
[46] Vornov JJ, Tasker RC, Coyle JT. Direct observation of the
agonist-specific regional vulnerability to glutamate, NMDA,
and kainate neurotoxicity in organotypic hippocampal
cultures. Exp Neurol 1991;114(1):11–22.
[47] Wettstein JG, Earley B, Junien JL. Central nervous system
pharmacology of neuropeptide Y. Pharmacol Ther
1995;65(3):397–414.
